BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:NIO752 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of NIO752\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07868328-766@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20290326
DTEND;VALUE=DATE:20290327
SUMMARY:NIO752: Phase 2 readout est. (NCT07868328)
DESCRIPTION:NIO752\, phase 2\, Progressive Supranuclear Palsy.\nStudy: A St
 udy to Evaluate the Safety\, Tolerability and Pharmacodynamics of NIO752 i
 n Primary Tauopathies\nEstimated primary completion: 26 March 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/nio752#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07868328
URL:https://assetmemo.bio/drug/nio752#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07498426-766@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20290720
DTEND;VALUE=DATE:20290721
SUMMARY:NIO752: Phase 3 readout est. (NCT07498426)
DESCRIPTION:NIO752\, phase 3\, Progressive Supranuclear Palsy.\nStudy: A St
 udy to Evaluate the Efficacy of NIO752 in Participants With Progressive Su
 pranuclear Palsy\nEstimated primary completion: 20 July 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/nio752#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07498426
URL:https://assetmemo.bio/drug/nio752#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
